| Size | Price | |
|---|---|---|
| 50mg | ||
| Other Sizes |
| Targets |
Ceforanide causes inhibition of bacterial cell wall synthesis by inactivating penicillin-binding proteins (PBPs). PBPs are enzymes essential for the final transpeptidation step required for cross-linking of peptidoglycan units, which are a component of the bacterial cell wall. By binding to and inactivating PBPs, ceforanide interferes with the cross-linking of peptidoglycan chains. This leads to weakening of the bacterial cell wall and ultimately bacterial cell death. Ceforanide is a bactericidal drug with activity against both Gram-positive and Gram-negative bacteria.
|
|---|---|
| ln Vitro |
Ceforanide has broad-spectrum in vitro antibacterial activity against Gram-positive and Gram-negative bacteria. Its spectrum of activity closely resembles that of cefamandole, but unlike cefamandole, it is less active against Gram-positive bacteria. The compound has bactericidal activity and is used in the sterilization in various medical procedures. It is effective for the treatment of respiratory, urinary, and skin infections.
|
| ln Vivo |
Ceforanide is a second-generation cephalosporin antibiotic with bactericidal activity. It is used for the treatment of infections caused by susceptible organisms, including respiratory, urinary, and skin infections. The compound's long half-life allows for less frequent dosing, which improves patient compliance. It has bactericidal activity and is used in the sterilization in various medical procedures.
|
| Enzyme Assay |
Ceforanide's activity is assessed using standard in vitro microbiological susceptibility testing methods. Minimum inhibitory concentration (MIC) determinations are performed against various bacterial strains. The compound's binding affinity to penicillin-binding proteins (PBPs) can be evaluated using competitive binding assays with radiolabeled penicillin. The compound's ability to inhibit the final transpeptidation step of peptidoglycan synthesis can be assessed.
|
| Cell Assay |
Cellular assays for ceforanide are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains. Bacterial growth inhibition is assessed by measuring optical density or by counting colony-forming units. The compound's bactericidal activity can also be evaluated.
|
| Animal Protocol |
In vivo animal model experiments for ceforanide would involve administration to animal models of infection to evaluate its efficacy. Studies may include models of respiratory, urinary, and skin infections. The compound's long half-life allows for less frequent dosing, which can be evaluated in pharmacokinetic studies. Such studies are essential for understanding the compound's in vivo behavior and therapeutic potential.
|
| ADME/Pharmacokinetics |
Ceforanide is known for its long half-life, which allows for less frequent dosing. Specific pharmacokinetic data is not extensively detailed in the available literature. As a second-generation cephalosporin, it is expected to have good tissue distribution and renal excretion. The compound's long half-life makes it a convenient option for once-daily or twice-daily dosing.
|
| Toxicity/Toxicokinetics |
Ceforanide is generally well-tolerated as a cephalosporin antibiotic. Common adverse effects associated with cephalosporins include gastrointestinal disturbances, hypersensitivity reactions (particularly in patients with penicillin allergy), and local reactions at the injection site. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
Ceforanide (CAS# 60925-61-3) is a semi-synthetic, beta-lactam, broad-spectrum, second-generation cephalosporin antibiotic. It has bactericidal activity and is used in the sterilization in various medical procedures. Ceforanide has broad-spectrum in vitro antibacterial activity against Gram-positive and Gram-negative bacteria. Its spectrum of activity closely resembles that of cefamandole, but it is less active against Gram-positive bacteria. It is known for its long half-life, which allows for less frequent dosing.
|
| Exact Mass |
519.09947
|
|---|---|
| CAS # |
60925-61-3
|
| PubChem CID |
43507
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.79 g/cm3
|
| Melting Point |
>150° (dec)
|
| Index of Refraction |
1.829
|
| LogP |
0.319
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
35
|
| Complexity |
905
|
| Defined Atom Stereocenter Count |
2
|
| Synonyms |
Ceforanido; Precef; Ceforanide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~240.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
